Immuneering Corporation (IMRX) Stock Forecast
IMRX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.71 / 5 from 7 analysts
- Price target
- $17.17 average of analyst targets
- Upside to target
- +378.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.29
- 52-week range
- $3.42 – $8.33
IMRX analyst ratings
7 analystsNumber of analysts at each rating.
IMRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IMRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.37 | −$0.27 | −$0.38 | +19.6% | 7 |
| Current fiscal year (2026) | −$1.12 | −$1.30 | −$1.03 | −$1.27 | +11.9% | 7 |
| Next fiscal year (2027) | −$1.26 | −$1.65 | −$0.29 | −$1.12 | −12.3% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IMRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $19.5M | $0 | $136.5M | 0.0% | 7 |
IMRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IMRX revenue: reported and forecast
IMRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.32 | −$0.31 | −$0.31 | −$0.31 | −$0.31 | −3.0% | 1 up · 2 down |
| Current fiscal year (2026) | −$1.14 | −$1.11 | −$1.12 | −$1.12 | −$1.12 | −1.6% | 3 up · 2 down |
| Next fiscal year (2027) | −$1.34 | −$1.29 | −$1.26 | −$1.26 | −$1.26 | −6.2% | 2 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IMRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IMRX beat in 9 of 12.
What analysts expect from IMRX
7 analysts cover Immuneering; their consensus rating is strong buy (4.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.17, 378.2% above the latest close of $3.59. Analysts expect earnings of −$1.12 per share for 2026, +11.9% from a year earlier. For 2027 the average estimate is −$1.26 per share on revenue of $19.5 million. Immuneering beat the EPS estimate in 9 of the last 12 quarters.
Related: IMRX income statement, IMRX key metrics, IMRX chart. See the IMRX stock overview for the latest quote and news.
IMRX forecast FAQ
What is Immuneering's price target?
The average analyst price target for Immuneering is $17.17, 378.2% above the latest close of $3.59.
Is Immuneering a buy, hold or sell?
Of 7 analysts covering Immuneering, 5 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Immuneering's EPS forecast?
Analysts forecast −$1.12 per share for 2026 (range −$1.30 to −$1.03); for 2027 the estimate is −$1.26.
When does Immuneering report earnings?
Immuneering is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.29.
Does Immuneering usually beat earnings estimates?
Immuneering reported EPS at or above the analyst estimate in 9 of the last 12 quarters.